You just read:

FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype

News provided by

Boehringer Ingelheim Pharmaceuticals

Oct 10, 2019, 08:30 ET